I, like many others, suffer from meibomian gland dysfunction(MGD): a progressive eye disease that gradually damages the eye's capacity to sustain a healthy tear film. This debilitating condition severely decreases our quality of life. Sadly, current available treatments don't offer much relief and fail to halt the disease's progression.  AZR-MD-001, an investigational new drug developed by Azura Opthalmics currently in Phase 3 Trial with a to-market-date estimated around 2026, shows a new avenue and efficacy of treatment for this disease.

AZR-MD-001 has shown promising results in stopping this disease's progression and providing a beacon of hope for millions of affected individuals. Furthermore, it could significantly enhance the quality of life and restore normalcy to those who have been suffering from this disease. So far, the drug has not yet been made broadly available to the public.

We, therefore, implore Azura Opthalmics to open up their investigational new drug AZR-MD-001 for the FDA Expanded Access Program. This program provides access to investigational drugs for patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives. While MGD may not be life threatening, for those with the disease it can be serious and substantially effect a person's daily functioning. 

AZR-MD-001 has been evidenced as safe and well tolerated after successful completion of Phase 2 clinical trials and has shown to improve signs and symptoms of MGD. AZR-MD-001's novel mechanism of action is also novel in a way not matched by existing therapeutic alternatives and provides a safer and non-systemic treatment option for MGD.

We only ask for the opportunity to be connected with this new and effective treatment and to live life without the constant discomfort of meibomian gland dysfunction. Help us maintain our quality of life by making AZR-MD-001 available through the FDA Expanded Access Program. It's time for us to take back control of our lives. Please sign this petition to help us raise awareness and connect patients this effective treatment.